Uric acid Reduction Ameliorates Transition to End-stage renal disease Study (URATE Study)

Uric acid Reduction Ameliorates Transition to End-stage renal disease Study (URATE Study) - URATE Study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001575

Enrollment

660

Registered

2008-12-15

Start date

2008-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia chronic kidney disease (CKD)

Interventions

administration of benzbromarone unadministration of benzbromarone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -serum creatinine level &#8805; 2.2mg/dl(male), &#8805; 1.7mg/dl(female) serum urate level &#8805; 7mg/dl -without acute alteration in renal function -stabilized patient under treatment within the CKD clinical practice guideline (by Japanese Society of Nephrology)

Exclusion criteria

Exclusion criteria: -patient with contraindications to benzbromarone -patient who takes warfarin

Design outcomes

Primary

Measure	Time frame
Death Doubling of serum creatinine Dialysis	—

Countries

Japan

Contacts

Public ContactHiroyuki Matsuda

Teikyo University EBM Center

URATE-Office@jhbri.com

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026